For instance, the Src family of oncogenes requires tyrosine kinase activity to transform thus it could be targeted by CRISPR/Cas9 directed toward the tyrosine kinase domain.75 Tang and Shrager proposed a practical clinical application of the CRISPR/Cas9 system to correct epidermal growth factor receptor (EGFR) mutations in patients with lung cancers. Here, EGFR is linked to lung carcinoma.